Invion Limited announced that Invion's Chief Operating Officer, Craig Newton will transition to the role of Chief Executive Officer effective 1 November 2019. Dr. Greg Collier will retire as MD and CEO, effective 31 October 2019. Dr. Collier will remain on the Board of Invion as a Non-Executive Director.

Dr. Collier joined Invion in May 2013. During his tenure as MD and CEO, Dr. Collier has overseen the development and spin-out of the Company's respiratory assets, and most recently the successful transaction with The Cho Group to acquire the Australian and New Zealand commercialisation rights for Photosoft™ technology. Invion leads the global development of the Photosoft™ technology under the auspices of an R&D services agreement between the Company and The Cho Group, an agreement that has seen significant advances over the past 15 months in preparation for clinical trials starting in fourth quarter of 2019.

Dr. Collier is leaving his executive role to focus on other areas and companies of interest. Craig Newton joined Invion as Chief Operating Officer in April 2018. Since that time, Craig has recruited a strong and experienced clinical development team.

Craig has over 30 years of experience in senior business and operational roles gained at various leading global companies including CSL, Serono UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals.